Biocracked
Longevity Metabolism Peptides Research Supplements Trending: supplements clinical trial longevity nad+ nootropics
**Approach: Conceptual metaphor. Palette: D, bold color field.** A single clear glass pipette dropper hangs just above a small glass dish on a saturated mustard-yellow seamless backdrop. One golden-amber droplet of oil falls from its tip, caught mid-air, with a faint ripple already spreading across the otherwise flat surface below. The dish is half-filled with clear fluid, a quiet nod to cerebrospinal fluid. The camera sits low and slightly off-axis, at a shallow 35° angle, with a macro lens and a softly blurred background. Large diffused studio light from the upper left gives crisp highlights on the glass and a clean, soft shadow on the yellow floor. A thin electric green reflection runs along the glass rim. The mood is sober and skeptical: a hopeful intervention producing a measurable ripple but no dramatic change. Photorealistic, with no text.
Longevity

2 g of DHA a Day Reached the Brain in APOE4 Carriers, but Memory Did Not Budge

Dr. Synapse · · 4 min read

The Headline

A two-year trial gave older adults 2 grams of DHA a day. It moved a key marker in the fluid around the brain, but it did not change brain volumes or cognitive test performance. The study, published in EBioMedicine by Yassine and colleagues, tested the idea in people carrying the APOE ε4 gene variant and in people without it. It is one of the clearer reality checks the omega-3 field has had.

What the Researchers Tested

DHA (docosahexaenoic acid) is the omega-3 fat that is abundant in brain tissue. APOE ε4 carriers have a higher Alzheimer's risk and altered omega-3 metabolism, so the hypothesis was reasonable. Maybe carriers with low omega-3 intake would benefit from a large DHA dose.

This was a phase IIa, randomised, double-blind, placebo-controlled trial (NCT03613844) run at the University of Southern California from September 2018 to May 2024. Participants were:

  • Aged 55-80 and free of dementia
  • Low in dietary DHA (under 200 mg/day)
  • Carrying at least one dementia risk factor

365 people were randomised from 739 screened. The mean age was 66.4, 58% were female, 39% were Hispanic, and 47% (173 people) were APOE ε4 carriers. Participants were split by whether they were willing to undergo a lumbar puncture (LP) to give cerebrospinal fluid (CSF). Within each group, they were randomised 1:1 to 2 g/day DHA or placebo, stratified by APOE ε4 status.

How Much DHA Reached the Brain?

The primary outcome was the change in the CSF DHA-to-arachidonic acid (AA) ratio at 6 months. CSF is a window into the central nervous system, so this ratio tests whether the supplement gets past the blood-brain barrier in a measurable way.

  • DHA group: ratio rose by 0.17 (95% CI 0.15-0.18)
  • Placebo group: ratio changed by -0.02 (95% CI -0.04 to -0.0004)
  • Difference: 0.19 (95% CI 0.16-0.21), p < 0.0001

The authors call this CNS target engagement: the supplement did what it was supposed to do biochemically.

The Twist: APOE4 Didn't Matter for Uptake

If you expected carriers to respond differently, the data say otherwise. The increase in CSF DHA/AA was independent of APOE ε4 status (interaction p = 0.71). Carriers and non-carriers both showed the rise, so in this trial the gene variant did not block DHA from reaching the central nervous system.

What Changed and What Didn't

Changed: the CSF DHA/AA ratio at 6 months.

Didn't change: brain volumes and cognitive performance over 24 months. The paper reports no treatment differences on those secondary and exploratory neuroimaging and cognitive measures.

The authors' interpretation is blunt. Despite biochemical target engagement, no differences in cognition or brain structure emerged. They conclude that future research should prioritise brain DHA metabolism over further supplementation trials.

Caveats Worth Knowing

  • Dropout was 38%, mainly due to COVID-19, which the authors report as a limitation of the 24-month data.
  • This was a phase IIa trial. Its primary aim was target engagement, and cognition and imaging were secondary or exploratory.
  • The population was non-demented and had low baseline DHA intake. The results don't speak to people who already have dementia or who eat plenty of fish.
  • Safety looked fine. Adverse events were comparable between groups, and no serious adverse events were attributed to treatment.

Practical Takeaways

Dose used: 2 g/day of DHA, compared with placebo. That is the only dose tested, so the trial can't say whether lower or higher doses behave differently.

Timing: The abstract does not specify time of day or meal pairing. It does show that the CSF marker moved by 6 months, while cognitive and imaging outcomes were followed for 24 months without a difference.

Who the findings apply to: adults aged 55-80 without dementia, with low dietary DHA (under 200 mg/day) and at least one dementia risk factor, whether or not they carry APOE ε4.

  • Anyone hoping a high-dose DHA capsule will protect memory or brain volume. This trial found no such effect over 24 months.
  • People already eating enough DHA. The trial enrolled only low-intake adults, so it offers no evidence for them.
  • People with dementia, who were not studied.
  • Anyone on blood thinners or with other medical conditions should ask a clinician before starting high-dose omega-3s. The paper doesn't address those situations.

The Bottom Line

DHA gets into the central nervous system at 2 g/day, even in APOE ε4 carriers. In this trial, though, getting there did not translate into better cognition or preserved brain structure over two years. The next question is what the brain does with the DHA once it arrives.

Source: Yassine et al., "CNS target engagement of high-dose DHA supplementation in older adults at risk for dementia: a randomised, double-blind, placebo-controlled trial," EBioMedicine. DOI: 10.1016/j.ebiom.2026.106316. PubMed 42315445. Funded by the National Institute on Aging (R01AG057684) and the ADDF (GC-201711-2014197). This article is for information only and is not medical advice.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

Share XFacebookLinkedInRedditWhatsApp
DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach 4, conceptual metaphor, in palette D, bold color field. A single old brass pocket watch, photographed from a slightly high three-quarter angle, sits on a saturated mustard-yellow seamless backdrop. The watch case is cracked open and its glass is gone. One half of the gear train is clean and polished. The other half is corroded, with a dull green-black patina. A few fine droplets of clear liquid sit on the corroded gears, and one tiny electric green (#00e676) glint of oxidation shows at the edge of the damage. Hard but slightly diffused studio strobe from the upper left casts a crisp, short shadow on the yellow. The macro lens gives a shallow depth of field, with the sharpest focus on the split between healthy and damaged gears. The mood is cautionary, precise and quietly unsettling. No text or numerals appear on the dial.
longevity

The Anti-Aging Compound Spermidine Has a Dark Side in Old T Cells

BY DR. SYNAPSE ·

Spermidine is widely promoted as an anti-aging polyamine, but a new mouse-derived cell study found it can sabotage a specific group of old immune cells. In senescence-like CD49d- CD8+ T cells, it cut mitochondrial respiration, depleted antioxidant reserves, and fragmented mitochondria, while neighboring CD49d+ cells were untouched. Cells from young mice responded differently, which makes age a key variable. This is preclinical work, not evidence of harm in humans, but it challenges the idea that spermidine helps every aging cell. Here's what the paper found and what it does and doesn't mean for you.
**Approach: Conceptual metaphor. Palette: D, bold color field.** A single analog wall clock with a blank white face and plain black hands, photographed straight-on against a saturated mustard-yellow backdrop. Its glass is slightly fogged. Several translucent multivitamin tablets, in the speckled orange-tan of a real multivitamin, rest on the clock's lower rim and in front of its face. One tablet is half-dissolved and leaves a faint haze on the glass. The clock hands sit just short of each other, hinting that the time barely shifted. Behind the clock a thin ghost shadow of a second clock hand falls a few degrees off, suggesting a nudge that isn't conclusive. A hair-thin electric green (#00e676) second hand adds a small accent. Soft, diffused studio light from the upper left creates gentle shadows on the yellow. The camera is at eye level with a shallow depth of field. The mood is wry and skeptical, curious but unconvinced.
longevity

A Cheap Multivitamin Nudged DHA Up—But the Aging Clocks Stayed Put

BY DR. SYNAPSE ·

Two years of a daily Centrum Silver gave older adults small bumps in DHA and omega-3 fatty acids and slowed the usual rise in creatinine, according to a COSMOS randomized trial analysis. Metabolomic risk scores for 16 chronic diseases also dipped, and all seven aging clocks trended 0.5 to 1.05 years younger. The twist is that none of it survived multiple-testing correction. Here is what the data show, what they don't, and who might care.
Approach: conceptual metaphor, with a natural palette. A single walnut is cracked open on a rough wooden board, and its two halves sit slightly apart. The halves are shot in tight macro from a low three-quarter angle. The walnut's brain-like folds are the focus. Between the halves, a thin cluster of fine, dark brown tannin-stained fibers stretches like a bridge. Beside it sits a small pile of shell fragments with a few strands of green walnut husk. A small, sharp, electric green (#00e676) leaf catches the light at the edge of the frame. The background is a softly blurred window-lit kitchen garden in leafy greens and warm earth tones. Soft natural daylight comes from the left and gives gentle shadows and visible texture on the nut's ridges. The mood is calm, curious and quietly scientific, with a fresh morning feel and no blue cast.
longevity

Urolithin A: The Walnut Gut Byproduct Tied to a Thicker Brain

BY NOVA CHEN ·

Eat a walnut and your gut bacteria turn its ellagitannins into urolithins, compounds that may be tied to how well your brain ages. In a 2-year MRI sub-study of the WAHA trial, bigger rises in urolithin A, urolithin C, and urolithin C glucuronide were associated with preserved cortical thickness among walnut eaters, mostly in right-hemisphere regions. The pattern was stronger in people with metabotype B gut profiles. But this is an association inside a randomized trial, not proof of cause, and it says nothing direct about urolithin A supplements. Here's what the data show, who might care, and who should stay skeptical.
Approach 1, macro science, in palette D, bold color field. Extreme close-up microscopy-style photograph of a dense colony of rod-shaped, slightly branched Bifidobacterium cells, rendered as real textured organic forms with soft translucent walls and subtle surface detail. The cells are warm cream and ivory, clustered in the center and thinning toward the edges. The whole backdrop is a saturated tomato-red to orange field, smooth and out of focus, so the bacteria stand out in sharp contrast. A few scattered tiny crystalline metabolite specks glow faintly electric green (#00e676) near the colony. Camera angle is straight-on, slightly oblique, with a very shallow depth of field. Lighting is soft, diffuse backlight with gentle rim highlights on the cell edges and no harsh shadows. The mood is vivid, curious and hopeful, scientific but warm, with no blue cast anywhere. No text.
longevity

This Gut Microbe Makes 5-AVAB, a Molecule That Tamed Inflammaging

BY NOVA CHEN ·

A gut microbe that quietly vanishes as we age may be doing more than anyone realized. A new Nature Aging study identifies Bifidobacterium pseudocatenulatum as consistently depleted across older adults in multiple Chinese cohorts. In naturally aged mice, giving it orally eased multiorgan inflammaging and extended healthspan. The team traced part of the effect to a metabolite called 5-AVAB, which also declines with age in humans. Here is what the study showed, what remains unproven in people, and how to read the hype responsibly.

This page is available in

English العربيةবাংলাČeštinaDeutschEspañolفارسیFrançaisHausaहिन्दीHrvatskiBahasa IndonesiaItaliano日本語Basa Jawa한국어NederlandsਪੰਜਾਬੀPolskiPortuguêsRomânăРусскийSrpskiTürkçeУкраїнськаTiếng Việt中文